Volume : 12, Issue : 10, October – 2025
Title:
REVIEW ON SEDENTRY LIFESTYLE AND OBESITY
Authors :
Sara Vinod Pachang*, Hrutik Kanhed, Dr. Swati P. Deshmukh
Abstract :
Because of a sedentary lifestyle, several life-related problems occur. Obesity is one of the most life-affecting factors that can be because by a sedentary lifestyle. Obesity is a problem increasing day by day in this modern lifestyle; obesity may further lead to various diseases. Polycystic ovarian syndrome/disease (PCOS). Being overweight is the most common example of being overweight; carrying extra weight can also cause a hormonal imbalance. Being overweight may increase the risk of heart attack and many heart-related problems. Due to working from home and sitting too long in the same workplace, and kids also prefer doing their work online, because of these habits, obesity is also increasing in young people and kids. Infertility because of obesity, child obesity and obesity in pregnant women. In this modern lifestyle, children become more obese because of technology; all the school work and other educational stuff are becoming technical, which is why students prefer to do their work while sitting in the same place. Sedentary individuals can lose between 20% and 40% of their muscle mass as adults. Long periods of inactivity are linked to metabolic syndrome, heart disease, and various mental health issues. In this lifestyle, we have to become more aware of the sedentary lifestyle and its consequences. The major complications that occur because of a sedentary lifestyle are infertility in men and women, childhood obesity, various heart diseases, type 2 diabetes, cancers, stroke and hypertension. There are many non-pharmacological and pharmacological management of obesity. Pharmacists and physicians have to play an important role to aware people and guiding them properly about a sedentary lifestyle and its bad impact on health.
Keywords: Sedentary lifestyle, Obesity, Body mass index (BMI), Pharmacological management, Role of pharmacist and health physician on public health.
Cite This Article:
Please cite this article in press Sara Vinod Pachang et al., Review On Sedentry Lifestyle And Obesity, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Faghri, P., Stratton, K., & Momeni, K. (2015). Sedentary lifestyle, obesity, and aging: Implication for prevention. Journal of Nutritional Disorders & Therapy, 5(1), e119.
2. Elward K, Larson EB (1992) Benefits of exercise for older adults. A review of existing evidence and current recommendations for the general population. Clinics in geriatric medicine 8: 35-50.
3. Bauman WA, Spungen AM (2008) Coronary heart disease in individuals with spinal cord injury: assessment of risk factors. Spinal Cord 46: 466-476.
4. Rey-López, J. P., Vicente-Rodríguez, G., Biosca, M., & Moreno, L. A. (2008). Sedentary behaviour and obesity development in children and adolescents. Nutrition, Metabolism & Cardiovascular Diseases, 18(3), 242–251.
5. Wolf AM, Gortmaker SL, Cheung L, Gray HM, Herzog DB, Colditz GA. Activity, inactivity, and obesity: racial, ethnic, and age differences among schoolgirls. Am J Public Health 1993;83(11):1625e7.
6. Shephard RJ. The obesity epidemic: a challenge to pediatric work physiologist? Pediatr Exerc Sci 2005;17:3e17.
7. Reilly, J. J., Armstrong, J., Dorosty, A. R., Emmett, P. M., Ness, A., Rogers, I., Steer, C., & Sherriff, A. (2005). Early life risk factors for obesity in childhood: Cohort study. BMJ, 330(7504), 1357.
8. Francis LA, Lee Y, Birch LL. Parental weight status and girls television viewing, snacking, and body mass indexes. Obes Res 2003;11:143-51.
9. Frohlich, E. D., Messerli, F. H., Reisin, E., & Dunn, F. G. (1983). The problem of obesity and hypertension. Hypertension, 5(5, Pt 2), III71–III78.
10. Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016). Management of obesity. The Lancet, 387(10031), 1947–1956.
11. Tsigos, C., Hainer, V., Basdevant, A., Finer, N., Fried, M., Mathus-Vliegen, E., Micic, D., Maislos, M., Roman, G., Schutz, Y., Toplak, H., & Zahorska-Markiewicz, B. (2008). Management of obesity in adults: European clinical practice guidelines. Obesity Facts, 1(2), 106–116.
12. Li C, Ford ES, Zhao G, Croft JB, Balluz LS, Mokdad AH. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005–2006. Prev Med 2010; 51: 18–23.
13. Ahima RS, Lazar MA. Physiology. The health risk of obesity—better metrics imperative. Science 2013; 341: 856–58.
14. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classifi cation misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 2012; 36: 286–94.
15. Kyrou I, Valsamakis G, Tsigos C: The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y AcadSci. 2006;1083:270–305.
16. Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 2014; 89: 335–45.
17. Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obesity (Silver Spring)2014; 22 (suppl 2): S1–3.
18. Lahti-Koski M, Männistö S, Pietinen P, Vartiainen E: Prevalence of weight cycling and its relation to health indicators in Finland. Obes Res 2005;13:333–341.
19. Scheen, A. J., & Lefèbvre, P. J. (1999). Pharmacological treatment of obesity: Present status. International Journal of Obesity, 23(Suppl 1), 47–53.
20. Kaplan, L. M. (2005). Pharmacological therapies for obesity. Gastroenterology Clinics of North America, 34(1), 91–104.
21. 21.Leonhardt, M., Hrupka, B., & Langhans, W. (1999). New approaches in the pharmacological treatment of obesity. European Journal of Nutrition, 38(1), 1–13.
22. Flechtner-Mors M, Ditschuneit HH, Yip I, Adler G. Blood pressure and plasma norepinephrine responses to dexfen¯uramine in obese postmenopausal women. Am J Clin Nutr 1998; 67: 611 ± 615.
23. Yen TT. Antiobesity and antidiabetic b-agonists : lessons learned and questions to be answered. Obes Res 1994; 2: 472 ± 480.
24. Goldstein DJ, Potvin JH. Long-term weight loss : the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647 ± 657.
25. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12(8):1197–211.
26. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581–8.
27. Sinha MK, Caro JF (1998) Clinical as-pects of leptin. Vitam and Horm 54:1–30
28. Stock MJ (1997) Sibutramine: a re-view of the pharmacology of a novel anti-obesity agent. Int J Obes21:S25–S29.
29. Ur E, Grossman A, Després JP (1996) Obesity results as a consequence of glucocorticoid induced leptin resistance. Horm Metab Res 28:744–747.
30. Woods SC, Seeley RJ, Porte D, Schwartz MW (1998) Signals that regulate food intake and energy homeostasis. Science 280:1378–1383.